RC18

Phase 3Biologic

RRemeGen Co., Ltd.

RC18 is one of 194 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

193

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Neuromyelitis OpticaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Myasthenia GravisActive, not recruiting

Multiple SclerosisActive, not recruiting

NephropathyActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Neuromyelitis OpticaPhase 3

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Myasthenia GravisPhase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

NephropathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

RC18

RRemeGen Co., Ltd.

Phase 3

2 2

Rituxan

Roche

Preclinical

61 3

Actemra

Cimzia

30 5

Enbrel

IImmunex

Preclinical

64 6

Remicade

OOrganon and Co

Preclinical

43 7

Arcoxia

Novartis

Preclinical

4 8

Actos

Takeda

Preclinical

2 9

Celexa

AbbVie

Preclinical

1 10

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis2 trials

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Terminated·RRemeGen Co., Ltd.·Phase 2·NCT02882087·60 enrolled

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Completed·RRemeGen Co., Ltd.·Phase 3·NCT03016013·479 enrolled

Systemic Lupus Erythematosus2 trials

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Completed·RRemeGen Co., Ltd.·Phase 3·NCT04082416·335 enrolled

Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Completed·RRemeGen Co., Ltd.·Phase 2·NCT02885610·249 enrolled

Nephropathy1 trial

A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

Completed·RRemeGen Co., Ltd.·Phase 2·NCT04291781·44 enrolled

Multiple Sclerosis1 trial

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT04625153·30 enrolled

Myasthenia Gravis1 trial

A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

Completed·RRemeGen Co., Ltd.·Phase 2·NCT04302103·29 enrolled

3 more indications

Neuromyelitis Optica1 trial

A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

Unknown status·RRemeGen Co., Ltd.·Phase 3·NCT03330418·166 enrolled

Antibody1 trial

A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects

Completed·RRemeGen Co., Ltd.·Phase 1·NCT04235933·36 enrolled

Primary Sjögren's Syndrome1 trial

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

Completed·RRemeGen Co., Ltd.·Phase 2·NCT04078386·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for RC18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RC18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RC18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RemeGen Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: RRemeGen Co., Ltd.

RC18

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis2 trials

Systemic Lupus Erythematosus2 trials

Nephropathy1 trial

Multiple Sclerosis1 trial

Myasthenia Gravis1 trial

Neuromyelitis Optica1 trial

Antibody1 trial

Primary Sjögren's Syndrome1 trial

References

Drug Info

Quick Facts

Related News